Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03201757 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
A Phase 3 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 3
- Development phase
- 523
- Enrollment target
NCT03201757 is a Phase 3 study that has completed, run by Alkermes. The registered enrollment target is 523 participants.
The verdict
NCT03201757, a Phase 3 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 523 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder
Interventions
- DRUG ALKS 3831
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 523 participants |
| Start Date | 2017-06-15 |
| Est. Completion | 2023-09-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03201757
The ClinicalTrials.gov registry entry for NCT03201757 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 523 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALKS 3831 is the first listed.
NCT03201757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03201757 about?
NCT03201757 is a clinical study titled "Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831". This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder
What is the current status of trial NCT03201757?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 523 participants. The study started on 2017-06-15. Estimated completion is 2023-09-06.
What interventions are being tested in trial NCT03201757?
The interventions under investigation include: ALKS 3831 (DRUG).
Who is sponsoring clinical trial NCT03201757?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.